{"id":"https://openalex.org/W1995834288","doi":"https://doi.org/10.1111/j.1755-5922.2010.00146.x","title":"Baseline Characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial Population: Comparison with Other Diabetes Prevention Trials","display_name":"Baseline Characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial Population: Comparison with Other Diabetes Prevention Trials","publication_year":2010,"publication_date":"2010-02-23","ids":{"openalex":"https://openalex.org/W1995834288","doi":"https://doi.org/10.1111/j.1755-5922.2010.00146.x","mag":"1995834288","pmid":"https://pubmed.ncbi.nlm.nih.gov/20184589"},"language":"en","primary_location":{"id":"doi:10.1111/j.1755-5922.2010.00146.x","doi":"https://doi.org/10.1111/j.1755-5922.2010.00146.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1755-5922.2010.00146.x","pdf_url":null,"source":{"id":"https://openalex.org/S73613154","display_name":"Cardiovascular Therapeutics","issn_l":"1755-5914","issn":["1755-5914","1755-5922"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cardiovascular Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5107829974","display_name":"Henry Krum","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801993434","display_name":"The Alfred Hospital","ror":"https://ror.org/01wddqe20","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2801993434","https://openalex.org/I4210163178"]},{"id":"https://openalex.org/I4210121067","display_name":"Monash Health","ror":"https://ror.org/02t1bej08","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I4210121067"]},{"id":"https://openalex.org/I56590836","display_name":"Monash University","ror":"https://ror.org/02bfwt286","country_code":"AU","type":"education","lineage":["https://openalex.org/I56590836"]}],"countries":["AU"],"is_corresponding":true,"raw_author_name":"Henry Krum","raw_affiliation_strings":["Monash University/Alfred Hospital, Melbourne, Victoria 3004, Australia. henry.krum@med.monash.edu.au","Monash University/Alfred Hospital, Melbourne, Victoria 3004, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Monash University/Alfred Hospital, Melbourne, Victoria 3004, Australia. henry.krum@med.monash.edu.au","institution_ids":["https://openalex.org/I2801993434","https://openalex.org/I4210121067","https://openalex.org/I56590836"]},{"raw_affiliation_string":"Monash University/Alfred Hospital, Melbourne, Victoria 3004, Australia","institution_ids":["https://openalex.org/I2801993434","https://openalex.org/I56590836"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027213857","display_name":"John J.V. McMurray","orcid":"https://orcid.org/0000-0002-6317-3975","observed_orcids":["https://orcid.org/0000-0002-6317-3975"]},"institutions":[{"id":"https://openalex.org/I7882870","display_name":"University of Glasgow","ror":"https://ror.org/00vtgdb53","country_code":"GB","type":"education","lineage":["https://openalex.org/I7882870"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"John J.V. McMurray","raw_affiliation_strings":["BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, UK","institution_ids":["https://openalex.org/I7882870"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069336249","display_name":"Edward S. Horton","orcid":"https://orcid.org/0000-0002-5670-3157","observed_orcids":["https://orcid.org/0000-0002-5670-3157"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Edward Horton","raw_affiliation_strings":["Brigham & Women's Hospital, Harvard University, Boston, MA, USA","Brigham and Women's Hospital, Harvard University, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Brigham & Women's Hospital, Harvard University, Boston, MA, USA","institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I136199984"]},{"raw_affiliation_string":"Brigham and Women's Hospital, Harvard University, Boston, MA, USA,","institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058498166","display_name":"Teresa E. Gerlock","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Teresa Gerlock","raw_affiliation_strings":["Novartis Pharmaceuticals, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016491875","display_name":"Bj\u00f6rn Holzhauer","orcid":"https://orcid.org/0000-0002-9209-757X","observed_orcids":["https://orcid.org/0000-0002-9209-757X"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Bjoern Holzhauer","raw_affiliation_strings":["Novartis Pharmaceuticals, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025315619","display_name":"Lineke Zuurman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Lineke Zuurman","raw_affiliation_strings":["Novartis Pharmaceuticals, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108086045","display_name":"Steven M. Haffner","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I165951966","display_name":"The University of Texas at San Antonio Health Science Center","ror":"https://ror.org/02f6dcw23","country_code":"US","type":"education","lineage":["https://openalex.org/I165951966","https://openalex.org/I45438204"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven M. Haffner","raw_affiliation_strings":["University of Texas Health Science Center, San Antonio, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas Health Science Center, San Antonio, TX, USA","institution_ids":["https://openalex.org/I165951966"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065924611","display_name":"Mary Angelyn Bethel","orcid":"https://orcid.org/0000-0002-7754-6584","observed_orcids":["https://orcid.org/0000-0002-7754-6584"]},"institutions":[{"id":"https://openalex.org/I40120149","display_name":"University of Oxford","ror":"https://ror.org/052gg0110","country_code":"GB","type":"education","lineage":["https://openalex.org/I40120149"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]},{"id":"https://openalex.org/I4210129944","display_name":"Oxford Centre for Diabetes, Endocrinology and Metabolism","ror":"https://ror.org/03myafa32","country_code":"GB","type":"facility","lineage":["https://openalex.org/I40120149","https://openalex.org/I4210129944","https://openalex.org/I4210147381"]},{"id":"https://openalex.org/I4405286153","display_name":"Duke Clinical Research Institute","ror":"https://ror.org/019mv4g96","country_code":"US","type":"facility","lineage":["https://openalex.org/I170897317","https://openalex.org/I4405286153"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"M. Angelyn Bethel","raw_affiliation_strings":["Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford, UK","Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford, UK","institution_ids":["https://openalex.org/I40120149","https://openalex.org/I4210129944"]},{"raw_affiliation_string":"Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA","institution_ids":["https://openalex.org/I4210126298","https://openalex.org/I4405286153"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049740900","display_name":"Rury R. Holman","orcid":"https://orcid.org/0000-0002-1256-874X","observed_orcids":["https://orcid.org/0000-0002-1256-874X"]},"institutions":[{"id":"https://openalex.org/I40120149","display_name":"University of Oxford","ror":"https://ror.org/052gg0110","country_code":"GB","type":"education","lineage":["https://openalex.org/I40120149"]},{"id":"https://openalex.org/I4210129944","display_name":"Oxford Centre for Diabetes, Endocrinology and Metabolism","ror":"https://ror.org/03myafa32","country_code":"GB","type":"facility","lineage":["https://openalex.org/I40120149","https://openalex.org/I4210129944","https://openalex.org/I4210147381"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Rury R. Holman","raw_affiliation_strings":["Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford, UK","institution_ids":["https://openalex.org/I40120149","https://openalex.org/I4210129944"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5107840885","display_name":"Robert M. Califf","orcid":"https://orcid.org/0000-0003-0231-3724","observed_orcids":["https://orcid.org/0000-0003-0231-3724"]},"institutions":[{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]},{"id":"https://openalex.org/I4405286153","display_name":"Duke Clinical Research Institute","ror":"https://ror.org/019mv4g96","country_code":"US","type":"facility","lineage":["https://openalex.org/I170897317","https://openalex.org/I4405286153"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert M. Califf","raw_affiliation_strings":["Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA","institution_ids":["https://openalex.org/I4210126298","https://openalex.org/I4405286153"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":12,"corresponding_author_ids":["https://openalex.org/A5107829974"],"corresponding_institution_ids":["https://openalex.org/I2801993434","https://openalex.org/I4210121067","https://openalex.org/I56590836"],"apc_list":{"value":2160,"currency":"USD","value_usd":2160},"apc_paid":null,"fwci":1.2062,"has_fulltext":false,"cited_by_count":10,"citation_normalized_percentile":{"value":0.80656204,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":96},"biblio":{"volume":"28","issue":"2","first_page":"124","last_page":"132"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":0.7523999810218811,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":0.7523999810218811,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.22179999947547913,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10144","display_name":"Blood Pressure and Hypertension Studies","score":0.017000000923871994,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/navigator-trial","display_name":"NAVIGATOR trial","score":0.9620000123977661},{"id":"https://openalex.org/keywords/nateglinide","display_name":"nateglinide","score":0.8989999890327454},{"id":"https://openalex.org/keywords/valsartan","display_name":"valsartan","score":1.0},{"id":"https://openalex.org/keywords/impaired-glucose-tolerance","display_name":"impaired glucose tolerance","score":0.9580000042915344},{"id":"https://openalex.org/keywords/impaired-fasting-glucose","display_name":"impaired fasting glucose","score":0.9639999866485596},{"id":"https://openalex.org/keywords/prediabetes","display_name":"prediabetes","score":0.8550000190734863},{"id":"https://openalex.org/keywords/diabetes-prevention","display_name":"diabetes prevention","score":0.7990000247955322},{"id":"https://openalex.org/keywords/cardiovascular-risk","display_name":"cardiovascular risk","score":0.6899999976158142},{"id":"https://openalex.org/keywords/metabolic-syndrome","display_name":"metabolic syndrome","score":0.902999997138977},{"id":"https://openalex.org/keywords/hypertension","display_name":"hypertension","score":0.6650000214576721},{"id":"https://openalex.org/keywords/dyslipidemia","display_name":"dyslipidemia","score":0.9810000061988831},{"id":"https://openalex.org/keywords/cardiovascular-disease-history","display_name":"cardiovascular disease history","score":0.6579999923706055},{"id":"https://openalex.org/keywords/baseline-characteristics","display_name":"baseline characteristics","score":0.6800000071525574},{"id":"https://openalex.org/keywords/renin-angiotensin-aldosterone-system-inhibitors","display_name":"renin-angiotensin-aldosterone system inhibitors","score":0.8889999985694885},{"id":"https://openalex.org/keywords/medication-use","display_name":"medication use","score":0.7630000114440918},{"id":"https://openalex.org/keywords/cardiovascular-risk-factors","display_name":"cardiovascular risk factors","score":0.46799999475479126},{"id":"https://openalex.org/keywords/cardiovascular-disease-prevention","display_name":"cardiovascular disease prevention","score":0.42899999022483826},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.5879999995231628}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9577208161354065},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7137467861175537},{"id":"https://openalex.org/C2780609358","wikidata":"https://www.wikidata.org/wiki/Q2087205","display_name":"Impaired glucose tolerance","level":4,"score":0.6839033365249634},{"id":"https://openalex.org/C2779463123","wikidata":"https://www.wikidata.org/wiki/Q2254797","display_name":"Nateglinide","level":4,"score":0.6700116395950317},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.6285400986671448},{"id":"https://openalex.org/C2777387769","wikidata":"https://www.wikidata.org/wiki/Q155472","display_name":"Valsartan","level":3,"score":0.6115809082984924},{"id":"https://openalex.org/C2780221984","wikidata":"https://www.wikidata.org/wiki/Q131191","display_name":"Body mass index","level":2,"score":0.559559166431427},{"id":"https://openalex.org/C2777185836","wikidata":"https://www.wikidata.org/wiki/Q3306264","display_name":"Impaired fasting glucose","level":5,"score":0.5562293529510498},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5443480014801025},{"id":"https://openalex.org/C2778096610","wikidata":"https://www.wikidata.org/wiki/Q1476525","display_name":"Dyslipidemia","level":3,"score":0.4900435209274292},{"id":"https://openalex.org/C2780578515","wikidata":"https://www.wikidata.org/wiki/Q657193","display_name":"Metabolic syndrome","level":3,"score":0.4770171642303467},{"id":"https://openalex.org/C2779668308","wikidata":"https://www.wikidata.org/wiki/Q2087205","display_name":"Prediabetes","level":4,"score":0.4523308575153351},{"id":"https://openalex.org/C84393581","wikidata":"https://www.wikidata.org/wiki/Q82642","display_name":"Blood pressure","level":2,"score":0.44155025482177734},{"id":"https://openalex.org/C2776193436","wikidata":"https://www.wikidata.org/wiki/Q236232","display_name":"Waist","level":3,"score":0.4316314458847046},{"id":"https://openalex.org/C500558357","wikidata":"https://www.wikidata.org/wiki/Q12152","display_name":"Myocardial infarction","level":2,"score":0.4201383590698242},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.3763170838356018},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3471890389919281},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000068756","descriptor_name":"Valsartan","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077715","descriptor_name":"Nateglinide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D001794","descriptor_name":"Blood Pressure","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D003510","descriptor_name":"Cyclohexanes","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003920","descriptor_name":"Diabetes Mellitus","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D003920","descriptor_name":"Diabetes Mellitus","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D003920","descriptor_name":"Diabetes Mellitus","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D003920","descriptor_name":"Diabetes Mellitus","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010649","descriptor_name":"Phenylalanine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D010649","descriptor_name":"Phenylalanine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011236","descriptor_name":"Prediabetic State","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D011236","descriptor_name":"Prediabetic State","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D011236","descriptor_name":"Prediabetic State","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D012107","descriptor_name":"Research Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012307","descriptor_name":"Risk Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013777","descriptor_name":"Tetrazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D014633","descriptor_name":"Valine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D014633","descriptor_name":"Valine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D018149","descriptor_name":"Glucose Intolerance","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D018149","descriptor_name":"Glucose Intolerance","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D018149","descriptor_name":"Glucose Intolerance","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D018149","descriptor_name":"Glucose Intolerance","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D018570","descriptor_name":"Risk Assessment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018579","descriptor_name":"Patient Selection","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047228","descriptor_name":"Angiotensin II Type 1 Receptor Blockers","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1111/j.1755-5922.2010.00146.x","doi":"https://doi.org/10.1111/j.1755-5922.2010.00146.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1755-5922.2010.00146.x","pdf_url":null,"source":{"id":"https://openalex.org/S73613154","display_name":"Cardiovascular Therapeutics","issn_l":"1755-5914","issn":["1755-5914","1755-5922"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cardiovascular Therapeutics","raw_type":"journal-article"},{"id":"pmid:20184589","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20184589","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cardiovascular therapeutics","raw_type":"Comparative Study"},{"id":"pmh:oai:eprints.gla.ac.uk:36589","doi":null,"is_oa":false,"landing_page_url":"http://eprints.gla.ac.uk/36589/","pdf_url":null,"source":{"id":"https://openalex.org/S4210235606","display_name":"ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)","issn_l":"2622-8912","issn":["2622-8912","2622-8920"],"is_oa":false,"is_in_doaj":true,"is_core":false,"listed_in":["doaj"],"host_organization":"https://openalex.org/I4405259220","host_organization_name":"Institut Agama Islam Negeri Langsa","host_organization_lineage":["https://openalex.org/I4405259220"],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Articles"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":19,"referenced_works":["https://openalex.org/W180946569","https://openalex.org/W1663109189","https://openalex.org/W1967140460","https://openalex.org/W2100271953","https://openalex.org/W2103714496","https://openalex.org/W2106244081","https://openalex.org/W2107732097","https://openalex.org/W2111432346","https://openalex.org/W2117057656","https://openalex.org/W2123744385","https://openalex.org/W2123946565","https://openalex.org/W2130717716","https://openalex.org/W2158822657","https://openalex.org/W2181092548","https://openalex.org/W2305118939","https://openalex.org/W2331274940","https://openalex.org/W2332951586","https://openalex.org/W2596500039","https://openalex.org/W4285719527"],"related_works":["https://openalex.org/W1967140460","https://openalex.org/W2315143570","https://openalex.org/W1523745876","https://openalex.org/W7095084058","https://openalex.org/W195432511","https://openalex.org/W2127201283","https://openalex.org/W7095351616","https://openalex.org/W7099638600","https://openalex.org/W1485027274","https://openalex.org/W1006952452"],"abstract_inverted_index":{"The":[0,132],"Nateglinide":[1],"and":[2,17,21,32,60,79,95,119,124,164,196,227,238,278,313,316,322],"Valsartan":[3],"Impaired":[4],"Glucose":[5],"Tolerance":[6],"Outcomes":[7],"Research":[8],"(NAVIGATOR)":[9],"trial":[10],"is":[11],"exploring":[12],"two":[13],"pharmacological":[14],"strategies":[15],"(nateglinide":[16],"valsartan,":[18],"both":[19],"alone":[20],"in":[22,24,39,241,333],"combination)":[23],"the":[25,33,55,149,199,302],"prevention":[26,250,336],"of":[27,35,54,68,86,129,136,144,154,179,184,187,193,198,203,230,247,288,320],"overt":[28],"diabetes":[29],"mellitus":[30],"(DM)":[31],"reduction":[34],"cardiovascular":[36,99,114,329],"disease":[37],"(CVD)":[38],"subjects":[40,137,307,332],"at":[41,264,325],"high":[42,152,165],"risk":[43,100,115,145,319,327],"for":[44,260,328],"these":[45],"events.":[46],"In":[47,300],"this":[48],"analysis,":[49],"we":[50],"provide":[51],"baseline":[52,265],"characteristics":[53],"randomized":[56],"NAVIGATOR":[57,242,267,303],"study":[58,304],"population":[59],"contrast":[61],"them":[62],"with":[63,126,148,171],"those":[64,246],"from":[65],"other":[66,127],"trials":[67,128],"DM":[69,130,249,335],"prevention.":[70,131],"Key":[71],"eligibility":[72],"criteria":[73,259],"include":[74],"impaired":[75,80],"glucose":[76,82],"tolerance":[77],"(IGT)":[78],"fasting":[81],"(IFG),":[83],"a":[84,142,182,191],"history":[85,183,192],"CVD":[87,117,185,283],"(in":[88,102],"patients":[89,103,180],"aged":[90,104],">":[91,96,105,173],"or":[92,97,106,174],"=50":[93],"years),":[94],"=1":[98],"factor":[101],"=55":[107],"years).":[108],"Baseline":[109],"demographic":[110],"characteristics,":[111],"laboratory":[112],"findings,":[113],"factors,":[116],"history,":[118],"medication":[120],"use":[121,263],"are":[122,323],"described":[123],"compared":[125],"full":[133],"analysis":[134],"set":[135],"(N":[138],"=":[139],"9306)":[140],"showed":[141],"clustering":[143],"factors":[146],"consistent":[147],"metabolic":[150,314],"syndrome:":[151],"rates":[153],"hypertension":[155],"(77.5%),":[156],"dyslipidemia":[157],"(44.7%),":[158],"increased":[159,219],"waist":[160],"circumference":[161],"(101.0":[162],"cm),":[163],"body":[166],"mass":[167],"index":[168],"(BMI)":[169],"(47.5%":[170],"BMI":[172],"=30":[175],"kg/m(2)).":[176],"A":[177],"minority":[178],"had":[181,190,201,209],"(24.3%);":[186],"these,":[188],"11.7%":[189],"myocardial":[194],"infarction":[195],"most":[197],"remainder":[200],"evidence":[202],"coronary":[204],"artery":[205],"disease.":[206],"Subjects":[207],"also":[208,254],"elevated":[210],"blood":[211],"pressure":[212],"(BP)":[213],"(predominantly":[214],"systolic)":[215],"(139.7/82.6":[216],"mm":[217],"Hg),":[218],"serum":[220],"low-density":[221],"lipoproteins":[222],"cholesterol":[223],"levels":[224,232],"(3.27":[225],"mmol/L),":[226],"borderline":[228],"elevation":[229],"triglyceride":[231],"(1.97":[233],"mmol/L).":[234],"Demographic":[235],"data,":[236],"BP,":[237],"lipid":[239],"profiles":[240],"were":[243,253],"similar":[244],"to":[245,296],"previous":[248,334],"trials,":[251],"which":[252,269],"based":[255],"largely":[256],"on":[257],"meeting":[258],"IGT.":[261],"Medication":[262],"among":[266],"subjects,":[268],"frequently":[270],"included":[271],"aspirin,":[272],"beta-blockers,":[273],"calcium":[274],"channel":[275],"blockers,":[276],"diuretics,":[277],"lipid-lowering":[279],"agents,":[280],"reflects":[281],"enhanced":[282,318],"risk.":[284],"However,":[285],"little":[286],"prescribing":[287],"renin-angiotensin-aldosterone":[289],"system":[290],"blockers":[291],"was":[292],"observed,":[293],"likely":[294],"due":[295],"protocol":[297],"exclusion":[298],"criteria.":[299],"conclusion,":[301],"comprises":[305],"prediabetic":[306],"who":[308],"typically":[309],"have":[310],"concurrent":[311],"BP":[312],"disturbances":[315],"an":[317],"CVD,":[321],"thus":[324],"higher":[326],"events":[330],"than":[331],"trials.":[337]},"counts_by_year":[{"year":2023,"cited_by_count":2},{"year":2017,"cited_by_count":2},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}